文丨木清近日,专注于仿制药CXO赛道的海纳医药向港交所发起冲刺。这些年,海纳医药做了好几次资本化尝试,先是在2023年冲击A股创业板未果,随后与科创板上市公司成都先导的“联姻”也宣告破裂,其上市之路布满荆棘。此次转战港股,公司营收利润双双下滑、核心赛道承压,“CXO+MAH”(医药外包+药品上市许可持有人)的商业模式也逐渐遇冷,在仿制药遭遇创新药挤压的当下,海纳医药能否得到市场的肯定?【A股折戟,...
Source Link文丨木清近日,专注于仿制药CXO赛道的海纳医药向港交所发起冲刺。这些年,海纳医药做了好几次资本化尝试,先是在2023年冲击A股创业板未果,随后与科创板上市公司成都先导的“联姻”也宣告破裂,其上市之路布满荆棘。此次转战港股,公司营收利润双双下滑、核心赛道承压,“CXO+MAH”(医药外包+药品上市许可持有人)的商业模式也逐渐遇冷,在仿制药遭遇创新药挤压的当下,海纳医药能否得到市场的肯定?【A股折戟,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.